Terapia dell’androgenizzazione cutanea nella donna

Riassunto

L’androgenizzazione cutanea femminile, espressa da iperseborrea, acne, ipertricosi e defluvium capitis, è determinata da un’iperstimolazione dell’apparato pilo-sebaceo da parte degli androgeni. Può essere idiopatica o sintomatica ed è efficacemente trattata con farmaci ad attività antiandrogena. In questa rassegna vengono illustrate le molecole dotate di attività antiandrogena, il loro meccanismo d’azione, gli effetti collaterali e gli schemi terapeutici più maneggevoli ed efficaci utilizzabili nella pratica clinica.

This is a preview of subscription content, access via your institution.

Bibliografia

  1. 1.

    Rosenfield RL. Pilosebaceous physiology in relation to hirsutism and acne. Clin Endocrinol Metab 15: 341, 1986.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Zachmann M, Prader A. Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone. J Clin Endocrinol Metab 30: 85, 1970.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Gafny M, Silbergeld A, Klinger B, Wasserman M, Laron Z. Comparative effects of GH, IGF-I and insulin on serum sex hormone binding globulin. Clin Endocrinol 41: 169, 1994.

    CAS  Article  Google Scholar 

  4. 4.

    Oakes SR, Haynes KM, Waters MJ, Herington AC, Werther GA. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J Clin Endocrinol Metab 75: 1368, 1992.

    CAS  PubMed  Google Scholar 

  5. 5.

    Toscano V, Sciarra F, Adamo MV, Petrangeli E, Foli S, Caiola S, Conti C. Is 3α-androstanediol a marker of peripheral hirsutism? Acta Endocrinol 99: 314, 1982.

    CAS  PubMed  Google Scholar 

  6. 6.

    Lobo R, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism of polycystic ovary syndrome. J Clin Endocrinol Metab 57: 393, 1983.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Toscano V, Balducci R, Bianchi P, Guglielmi R, Mangiantini A, Rossi FG, Colonna LM, Sciarra F. Two different pathogenetic mechanisms may play a role in acne and in hirsutism. Clin Endocrinol 39: 551, 1993.

    CAS  Article  Google Scholar 

  8. 8.

    Imperato-McGinley J, Gautier T, Cai L, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 76: 524, 1993.

    CAS  PubMed  Google Scholar 

  9. 9.

    Hammerstein J, Cupceancu B. Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch Med Wochenschr 94: 829, 1969.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Molinatti GM, Messina M, Manieri C, Massucchetti C, Biffignandi P. Current approaches to the treatment of virilizing syndromes. In: Molinatti GM, Martini L, James VHT (Eds.) Androgenization in women. Raven Press, New York, 1983, p 179.

    Google Scholar 

  11. 11.

    Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani A.R. Treatment of hirsutism: comparison between different antiandrogens with central and peripheral effects. Fertil Steril 71: 445, 1999.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Kelestimur F. Diane 35 and spironolactone combination in the treatment of hirsutism. Clin Endocrinol 54: 699, 2001.

    CAS  Article  Google Scholar 

  13. 13.

    MILTS. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 56: 275, 1997.

    Article  Google Scholar 

  14. 14.

    Basinger GT, Gitte RB. Antiandrogenic effect of spironolactone in rats. J Urol 111: 77, 1974.

    CAS  PubMed  Google Scholar 

  15. 15.

    Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab 51: 429, 1978.

    Article  Google Scholar 

  16. 16.

    Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol 52: 587, 2000.

    CAS  Article  Google Scholar 

  17. 17.

    Messina M, Manieri C, Musso MC, Pastorino R. Oral and topical spironolactone therapies in skin androgenization. Panminerva Med. 32: 1, 1990.

    Google Scholar 

  18. 18.

    Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 85: 89, 2000.

    CAS  PubMed  Google Scholar 

  19. 19.

    Ibáñez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 85: 3251, 2000.

    PubMed  Google Scholar 

  20. 20.

    Muderris II, Bayram F. Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. J Endocrinol Invest 22: 165, 1999.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Vigersky RA, Mehlman I, Glass AR, Smith CE. Treatment of hirsute women with cimetidine. N Engl J Med 303: 1042, 1980.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Cilotti A, Danza G, Serio M. Clinical application of 5a-reductase inhibitors. J Endocrinol Invest 24: 199, 2001.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Fruzzetti F, de Lorenzo D, Parrini D, Ricci C. Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab 79: 831, 1994.

    CAS  PubMed  Google Scholar 

  24. 24.

    Manieri C, Grosso T, Di Bisceglie C, Fornengo R, Tagliabue M, Martina V, Taliano M, Bertagna A. Finasteride in idiopathic hirsutism: its effectiveness in blocking 5α-reductase. Int J Immunopathol Pharmacol 10: 139, 1997.

    CAS  Google Scholar 

  25. 25.

    Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 75: 496, 2001.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 312: 83, 1996.

    CAS  Article  Google Scholar 

  27. 27.

    Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 49: 579, 1994.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Conn JJ, Jacobs HS. Managing hirsutism in gynaecological practice. Br J Obstet Gynaecol 105: 687, 1998.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Escobar-Morreale HF, Lasuncion MA, Sancho J. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil Steril 74: 816, 2000.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Harvengt C. Effect of oral contraceptive use on the incidence of impaired glucose tolerance and diabetes mellitus. Diabetes Metabolism 18: 71, 1992.

    CAS  Google Scholar 

  31. 31.

    Pascale M-M, Pugeat M, Roberts M, Rousset H, Déchaud H, Dutrieux-Berger N, Tourniaire J. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol 41: 571, 1994.

    CAS  Article  Google Scholar 

  32. 32.

    Manieri C, Di Bisceglie C, Fornengo R, Grosso T, Zumpano E, Calvo F, Berardengo E, Volante M, Papotti M. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis. J Endocrinol Invest 21: 128, 1998.

    CAS  PubMed  Google Scholar 

  33. 33.

    Efstathiadou Z, Tsatsoulis A. Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist. Fertil Steril 75: 59, 2001.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (Nafarelin). J Clin Endocrinol Metab 63: 854, 1986.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Carmina E, Lobo RA. Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Human Reprod 12: 663, 1997.

    CAS  Article  Google Scholar 

  36. 36.

    Vidal-Puig AJ, Munoz-Torres M, Jodar-Gimeno E, Garcia-Calvente CJ, Lardelli P, Ruiz-Requena ME, Escobar-Jimenez F. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol 130: 333, 1994.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, Castello R, Moghetti P. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab 85: 81, 2000.

    CAS  PubMed  Google Scholar 

  38. 38.

    Kokaly W, McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. Clin Endocrinol 52: 379, 2000.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dott. Cataldo Di Bisceglie.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Manieri, C., Di Bisceglie, C., Tagliabue, M. et al. Terapia dell’androgenizzazione cutanea nella donna. L’Endocrinologo 2, 110–118 (2001). https://doi.org/10.1007/BF03344394

Download citation